Latest news with #RenalyxHealthSystems
The Print
a day ago
- Business
- The Print
Renalyx Health Systems to invest Rs 800 cr for setting up 3 dialysis machine production units
Currently, the company manufactures RxT 17 through contract manufacturing and with the launch of RxT 21, it will set up its own facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra, Renalyx Health Systems Founder and Director Shyam Vasudeva Rao told PTI. RENALYX – RxT 21 machine is world's first fully indigenous, AI and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility, the company said. Mumbai, Jun 11 (PTI) Bengaluru-headquartered Renalyx Health Systems on Wednesday said it is planning to invest Rs 800 crore in the next four years to set up three manufacturing units to produce RENALYX – RxT 21 machine that will help dialysis affordable and accessible to a larger population. This is expected to raise the manpower of the company to over 500 people in 1-2 years from the current 100, he added. 'RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification, a mandatory conformity marking for products sold within the European Economic Area (EEA). We are aiming for an annual capacity of 5,000 machines in the company-owned manufacturing units,' he added. The Indian CDSCO (Central Drugs Standard Control Organisation) approval of the machine is in its final stages and is expected by July this year, while the US FDA approval process is underway and anticipated by March 2026, he said. When asked how the company is planning to raise Rs 800 crore for setting up the manufacturing units, Rao said, the company will get it through a mix of foreign direct investment (FDIs), equity and debt. 'The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. We are also planning to go public within the next three years,' he added. Renalyx Health Systems is a technology innovation company which is focused on delivering inclusive solutions for comprehensive renal care. With initial deployments of the machine planned in Maharashtra and Karnataka, the company will go for rapid pan-India distribution of RxT 21 with its partners as well as exports to other countries. Rao said the company has penetrated international markets, and has secured orders from South Africa, the USA, and Europe. In India, Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres and hospitals to make renal care available to a large number of people. PTI SM HVA This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Time of India
a day ago
- Business
- Time of India
Renalyx Health Systems to invest Rs 800 cr for setting up 3 dialysis machine production units
Mumbai: Bengaluru-headquartered Renalyx Health Systems on Wednesday said it is planning to invest Rs 800 crore in the next four years to set up three manufacturing units to produce RENALYX - RxT 21 machine that will help dialysis affordable and accessible to a larger population. RENALYX - RxT 21 machine is world's first fully indigenous, AI and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility, the company said. Currently, the company manufactures RxT 17 through contract manufacturing and with the launch of RxT 21, it will set up its own facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra, Renalyx Health Systems Founder and Director Shyam Vasudeva Rao told PTI. This is expected to raise the manpower of the company to over 500 people in 1-2 years from the current 100, he added. "RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification, a mandatory conformity marking for products sold within the European Economic Area (EEA). We are aiming for an annual capacity of 5,000 machines in the company-owned manufacturing units," he added. The Indian CDSCO (Central Drugs Standard Control Organisation) approval of the machine is in its final stages and is expected by July this year, while the US FDA approval process is underway and anticipated by March 2026, he said. When asked how the company is planning to raise Rs 800 crore for setting up the manufacturing units, Rao said, the company will get it through a mix of foreign direct investment (FDIs), equity and debt. "The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. We are also planning to go public within the next three years," he added. Renalyx Health Systems is a technology innovation company which is focused on delivering inclusive solutions for comprehensive renal care. With initial deployments of the machine planned in Maharashtra and Karnataka, the company will go for rapid pan-India distribution of RxT 21 with its partners as well as exports to other countries. Rao said the company has penetrated international markets, and has secured orders from South Africa, the USA, and Europe. In India, Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres and hospitals to make renal care available to a large number of people. PTI
Time of India
2 days ago
- Business
- Time of India
Renalyx launches India's first indigenous AI based smart hemodialysis machine, makes renal care accessible and affordable
Renalyx dignitaries with AI based smart hemodialysis machine MUMBAI: Renalyx Health Systems Pvt. Ltd., a pioneering technology innovation company in renal care, has launched RENALYX – RxT 21, India's first fully indigenous, AI and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility. Price starting at INR 6.70 lakh - significantly lower than the imported machines - RENALYX – RxT 21 will make dialysis affordable and accessible to a larger population and bridge the demand-supply gap in the renal care across semi-urban and rural regions. According to Pradhan Mantri National Dialysis Program (PMNDP) data, approximately 2.2 lakh new cases of End-Stage Renal Disease (ESRD) are reported in India each year, creating an additional demand for 3.4 crore dialysis sessions annually Completely designed and manufactured in India, RENALYX – RxT 21 leverages latest technologies including cloud-based telenephrology platforms to offer safety and quality care to kidney patients, end-stage renal disease (ESRD) patients especially those with cardiovascular, pulmonary and acute kidney injury-related issues. RENALYX – RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification. Renalyx has plans to invest INR 800 crores in the next four years to build the manufacturing capacity of 5,000 machines by FY25-26 and will develop additional capacity of 1500 machines by FY27-28. The company also have plans to manufacture consumables indigenously. The company has manufacturing facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra to support its scale-up plans and meet the growing demand. The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. Renalyx also has plans to go public within the next three years. With initial deployments of the machine planned in Maharashtra and Karnataka, Renalyx will go for rapid pan-India distribution of RENALYX – RxT 21 with its partners as well as exports to other countries. The company has successfully penetrated international markets, securing orders from South Africa, the USA, and Europe. Commenting on the launch of Rx T21, Dr. Shyam Vasudeva Rao, Founder & Director of Renalyx Health Systems said, 'Our cutting-edge hemodialysis machine will revolutionise the renal care by making dialysis facility affordable and accessible, thus strengthening the kidney healthcare infrastructure of the country. By bringing dialysis services closer to patients' homes, RxT 21 will help in addressing the rising Chronic Kidney Disease (CKD) burden and ESRD patients. Our indigenously developed hemodialysis machine will play a game-changing role in reducing dialysis expense, thus ensuring better healthcare impact. Going forward, we have plans to scale up our manufacturing capacity and reduce the Total Cost of Ownership of RxT 21 by 40% compared to that of imported machines. We have plans to develop a broader range of technologically advanced machines over the next three years, including a home dialysis model. In line with the government vision of 'Make in India Make for the World', we aim to export our machine to various countries to make a larger impact on renal care infrastructure globally. We aim to become one of the world's leading producers and exporters within the next five years.' The Indian CDSCO approval of the machine is in its final stages and is expected by July 2025, while the U.S. FDA approval process is underway and anticipated by March 2026. The RENALYX – RxT 21 machines are equipped with advanced features such as Integrated Nephrology Information System (NIS) on the cloud, AI based smart algorithms, Electronic Medical Records (EMR) integration, remote diagnostics and alerts through real-time telemetry, Advanced image processing, Internet of Medical Things (IoMT) capabilities for continuous performance monitoring and clinical oversight. Thanks to these advanced features, doctors can remotely access patients' EMR, current settings of the dialysis machine and patients' critical event history to take action and advise necessary treatment and care. Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres and hospitals to make renal care available to a large number of people. The company has set up local service teams and created technician training programs to ensure smooth roll-out of the smart machines. The company will set up franchisee centres across India along with its partners. The company, in collaboration with its partner, will set up franchise centres across India and in international markets. In addition, Renalyx has awarded manufacturing license to Bharat Electronics Ltd. (BEL) to produce 6,000 RENALYX – RxT 17 in the next three years. RENALYX – RxT 17 is a previously launched dialysis machine by Renalyx which comes with standard features and facilities. With RENALYX – RxT 21 and RxT 17, Renalyx aims to play its role in making dialysis services affordable and accessible to the rural areas due to the recurring nature of the treatment.
New Indian Express
2 days ago
- Business
- New Indian Express
Renal care firm Renalyx to invest Rs 800 crore in Karnataka manufacturing plants
MUMBAI: Bengaluru-based Renalyx Health Systems, which is into renal care, has launched what it claims to be the world's first fully indigenous, AI and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility. The company also claimed that they are the sixth in the world and the first company in the country to produce an advanced dialysis machine with EU CE certification. The company has also announced Rs 800 crore of investments in its Bengaluru manufacturing facility over the next four years. Called the Renalyx RxT 21, the machine comes for Rs 6.70 lakh, which is significantly lower than the price of imported machines, thus helping make dialysis affordable and accessible to a larger population and bridge the demand-supply gap in the renal care across semi-urban and rural regions.
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Renalyx launches smart dialysis unit RxT21, plans ₹800 crore boost
Bengaluru-based Renalyx Health Systems has launched a cloud-enabled and AI-powered smart haemodialysis machine with real-time remote monitoring and clinical connectivity. Named RxT21 and priced at ₹6.7 lakh, the machine is claimed to be significantly cheaper than imported alternatives. Comparable models in the market cost 20–25 per cent more, the company said. Renalyx plans to invest ₹800 crore over the next four years to build manufacturing capacity for an initial 5,000 RxT21 machines by FY26, with an additional 1,500-unit capacity by FY28. The company will also manufacture consumables indigenously. Renalyx has manufacturing facilities in Bengaluru and Mysuru in Karnataka and in Mumbai, Maharashtra, to support its scale-up plans and meet rising demand. CDSCO approval for the RxT21 is in its final stages and expected by July 2025, while the USFDA approval process is under way and anticipated by March 2026, the company told Business Standard. Shyam Vasudeva Rao, founder and director of Renalyx Health Systems, said RxT21 would bring dialysis closer to patients' homes, helping reduce dropout rates. Remote monitoring is critical, especially as many rural patients miss their dialysis sessions—typically three per week—due to travel challenges. 'With this machine, we can monitor a patient's vitals during dialysis and stop the process immediately if any issue arises, reducing the need for highly trained manpower at rural centres,' Rao said. According to data from the Pradhan Mantri National Dialysis Programme (PMNDP), approximately 220,000 new cases of end-stage renal disease (ESRD) are reported in India annually, generating demand for 34 million dialysis sessions. Industry estimates suggest the country currently performs 21–22 million sessions annually, supported by 50,000 dialysis machines, 5,000 centres, and about 3,000 practising nephrologists. As the dialysis sector grows, domestic medical device makers are entering the fray. Currently, most dialysis machines in India are imported, with German firm Fresenius leading the market. Industry estimates indicate that 35,000 of the 50,000 machines deployed in India are from Fresenius. These machines typically cost between ₹7–8 lakh, excluding the cost of dialysers (the filtering unit) and other consumables. Founded in 2012, Renalyx also produces the RxT17 dialysis machine, which has standard features. It has licensed Bharat Electronics (BEL) to manufacture 6,000 RxT17 units over the next three years. The company has invested ₹52 crore so far in manufacturing and R&D. 'The company plans to raise funds through equity sales, supported by strong interest from Indian and international investors. In addition, it will raise debt, with promoters also infusing capital. Renalyx intends to go public within the next three years,' it said in a statement. Initial deployments of the RxT21 are planned in Maharashtra and Karnataka. Renalyx will then pursue rapid pan-India distribution of the machine in partnership with domestic collaborators and also export to global markets. The company has already secured orders from South Africa, the United States, and Europe.
